

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/584,661
		<b>Filing Date</b>	June 26, 2006(Int'l FD12/18/04)
		<b>First Named Inventor</b>	Kocsis
		<b>Art Unit</b>	To be assigned
		<b>Examiner Name</b>	To be assigned
<b>Sheet</b> 1	<b>of</b> 1	<b>Attorney Docket Number</b>	0103-0004/2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.K./		LEANDER, Fluoxetine, a Selective Serotonin-Uptake Inhibitor, Enhances the Anticonvulsant Effects of Phenytoin, Carbamazepine. . . (LY201116), Epilepsia 33(3): 573-576 (1992)	
/J.K./		RAJU et al., Effect of Fluoxetine on Maximal Electroshock Seizures in Mice: Acute VS Chronic Administration, Pharm. Res. 39(6): 451-454 (1999)	
/J.K./		RAPEPORT et al., Absence of a Sertraline-Mediated Effect on the Pharmacodynamics of Carbamazepine, J. Clin. Psych. 57: 20-23 (1996)	
/J.K./		PCT International Search Report for PCT/HU2004/000123 (2004)	
/J.K./		PCT Written Opinion for PCT/HU2004/000123 (2004)	
/J.K./		PCT International Preliminary Report on Patentability (IPER) for PCT/HU2004/000123 (2004)	

<b>Examiner Signature</b>	/Jennifer Kim/	<b>Date Considered</b>	06/17/2011
---------------------------	----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.